CoChat

Off-target effects in CRISPR/Cas9 gene editing

Open access
Guo, Congting, Ma, Xiaoteng, Gao, Fei, Guo, Yuxuan · 2023 · Frontiers in Bioengineering and Biotechnology

The DOI matches its Crossref record; 106 of the 108 references it cites were found in a registry or an index; 151 of the 237 sources its claims cite were checked for support.

Abstract

Gene editing stands for the methods to precisely make changes to a specific nucleic acid sequence. With the recent development of the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system, gene editing has become efficient, convenient and programmable, leading to promising translational studies and clinical trials for both genetic and non-genetic diseases. A major concern in the applications of the CRISPR/Cas9 system is about its off-target effects, namely the deposition of unexpected, unwanted, or even adverse alterations to the genome. To date, many methods have been developed to nominate or detect the off-target sites of CRISPR/Cas9, which laid the basis for the successful upgrades of CRISPR/Cas9 derivatives with enhanced precision. In this review, we summarize these technological advancements and discuss about the current challenges in the management of off-target effects for future gene therapy.

Overview

CoChat Summary

TL;DR

This review summarizes methods for predicting and detecting CRISPR/Cas9 off-target effects and strategies for improving editing specificity. It emphasizes persistent trade-offs between accuracy and sensitivity and the difficulty of assessing off-target effects in vivo and in patients.

Key findings

  • Off-target effects remain a major challenge for CRISPR/Cas9; Cas9 tolerates up to 3 mismatches between sgRNA and genomic DNA, and sgRNA-independent off-target effects also occur.
  • In silico tools are convenient but biased toward sgRNA-dependent off-target effects and require experimental validation; examples include CasOT, Cas-OFFinder, FlashFry, Crisflash, MIT, CCTop, CROP-IT, CFD, DeepCRISPR, and Elevation.
  • Experimental detection methods vary widely: Digenome-seq detects indels at 0.1% frequency or lower but needs ∼400–500 million reads for the human genome; SITE-seq needs ∼0.62–2.46 million reads but only 10% of positive hits were validated by targeted sequencing; CIRCLE-seq needs ∼4–5 million reads but has a high false positive rate; GUIDE-seq detects indel frequencies as low as 0.03% but captures only 30%–50% of all DSBs.
  • Specificity strategies include high-fidelity Cas9 variants (eSpCas9, SpCas9-HF1, hypaCas9, evoCas9), sgRNA length/chemical modification, DSB-independent base editors, and delivery methods such as RNP electroporation and LNPs; evoCas9, SpCas9-HF1, and eSpCas9 reduced off-target sites by 98.7%, 95.4%, and 94.1%, respectively, in one comparison.

Methods

  • This is a narrative review, not a primary experimental study; no original sample, dataset, or systematic meta-analysis is described.
  • It synthesizes in silico prediction tools, cell-free, cell culture-based, and in vivo off-target detection methods, plus strategies to reduce off-target effects.
  • Main analysis is qualitative comparison of advantages and disadvantages, organized in Tables 1 and 2 and supported by cited literature.

Limitations

  • The paper states that limitations remain in balancing accuracy versus sensitivity of off-target detection techniques, and that direct assessment of off-target effects in vivo and in patients is particularly challenging.
  • It notes that in silico predictions are biased toward sgRNA-dependent off-target effects and need experimental validation, and that many experimental methods have limitations such as high cost, high sequencing coverage, low sensitivity, false positives, false negatives, or dependence on chromatin accessibility.
  • Evident from the text: as a review, it provides no new experimental data, and it states there is currently no standardized approach to confirm the sensitivity of Discover-seq.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fbioe.2023.1143157

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 Schematics of experimental methods for genome-wide off-target prediction.
FIGURE 1 Schematics of experimental methods for genome-wide off-target prediction.CC BY · PubMed Central

Verification

Claims the paper makes

78 Valid · 10 Not valid · 21 Not checked · 25 Own results and interpretations

82 more claims · 52 with their cited sources checked

Create a free account to see all 134 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 20
  • It may state two separate claims as one. 33

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Cited by

See all 704

Metadata

Authors
Guo, C., Ma, X., Gao, F., & Guo, Y.
Affiliations
  • Peking University (CN)
  • Capital Medical University (CN)
Corresponding author
  • Gao, Fei
  • Guo, Yuxuan
Venue
Frontiers in Bioengineering and Biotechnology
Published
2023-03-09
Volume
11
Pages
1143157-1143157
ISSN
2296-4185 (ISSN-L)
OpenAlex
W4323666400
Cited by
704
References
108
Citations by year
2026: 225 · 2025: 290 · 2024: 154 · 2023: 35
FWCI
17.24
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Bioengineering and Biotechnology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (82100349, 82222006, 32100660, 82170367)
  • Beijing Nova Program (Z211100002121003, 20220484205)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
CRISPR/Cas9, off-target effects, genome editing, gene therapy, Cas9 variants

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.